Cardiff Oncology (NASDAQ:CRDF) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Cardiff Oncology (NASDAQ:CRDF) from a strong sell rating to a sell rating in a report published on Saturday,Wall Street Zen reports.

Several other equities research analysts have also commented on CRDF. TD Cowen lowered Cardiff Oncology from a “buy” rating to a “hold” rating in a research note on Monday, June 1st. HC Wainwright lowered Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Craig Hallum cut Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a report on Wednesday, June 3rd. William Blair cut Cardiff Oncology from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 11th. Finally, Weiss Ratings downgraded shares of Cardiff Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 19th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Cardiff Oncology has an average rating of “Hold” and an average price target of $7.50.

Cardiff Oncology Stock Up 0.9%

Shares of NASDAQ CRDF opened at $1.09 on Friday. Cardiff Oncology has a 52-week low of $0.76 and a 52-week high of $3.31. The firm has a fifty day moving average of $1.02 and a 200-day moving average of $1.44. The stock has a market capitalization of $84.79 million, a PE ratio of -1.82 and a beta of 1.46.

Cardiff Oncology (NASDAQ:CRDF) last issued its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%.The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.06 million. Equities research analysts expect that Cardiff Oncology will post -0.63 EPS for the current fiscal year.

Insider Activity at Cardiff Oncology

In other news, Director Gary W. Pace acquired 30,000 shares of the stock in a transaction on Thursday, June 18th. The stock was bought at an average price of $1.22 per share, with a total value of $36,600.00. Following the completion of the transaction, the director directly owned 1,356,376 shares of the company’s stock, valued at $1,654,778.72. The trade was a 2.26% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Mani Mohindru acquired 24,703 shares of the stock in a transaction on Thursday, June 18th. The stock was purchased at an average cost of $1.21 per share, with a total value of $29,890.63. Following the transaction, the chief executive officer directly owned 24,703 shares of the company’s stock, valued at $29,890.63. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CRDF. Laurion Capital Management LP grew its holdings in Cardiff Oncology by 7.3% during the 4th quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock valued at $7,437,000 after purchasing an additional 180,866 shares in the last quarter. Acorn Capital Advisors LLC lifted its holdings in Cardiff Oncology by 39.3% in the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock worth $4,042,000 after buying an additional 553,317 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock worth $4,723,000 after buying an additional 104,409 shares in the last quarter. Franklin Resources Inc. purchased a new position in Cardiff Oncology in the 4th quarter valued at about $3,388,000. Finally, State Street Corp boosted its position in Cardiff Oncology by 4.0% in the 4th quarter. State Street Corp now owns 1,191,647 shares of the company’s stock valued at $3,349,000 after buying an additional 45,288 shares during the last quarter. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.